The University of Southampton
University of Southampton Institutional Repository

The cost-effectiveness of left ventricular assist devices in end stage heart failure

Hutchinson, Julia, Scott, David A., Clegg, Andrew J., Loveman, Emma, Royle, Pam, Bryant, Jackie and Colquitt, Jill L. (2008) The cost-effectiveness of left ventricular assist devices in end stage heart failure Expert Review of Cardiovascular Therapy, 6, (2), pp. 175-185. (doi:10.1586/14779072.6.2.175).

Record type: Article


With a limited supply of donor hearts, individuals with end-stage heart failure have been offered hope through the use of mechanical devices. Left ventricular-assist devices (LVADs) are a technology designed to work in parallel with the heart but have yet to see widespread use since uncertainty remains as to the cost–effectiveness of this evolving new technology. We have systematically reviewed evidence of cost–effectiveness for LVADs in the bridge-to-transplant and long-term chronic support indications. A total of 18 studies reporting costs were identified. Of these, only four studies reported results in cost–effectiveness terms; two in cost per life-year saved and two in cost per quality-adjusted life-year (QALY). The majority of the other studies were simple cost summations (cost per day or incremental cost) without consideration of efficacy. In the bridge-to-transplant indication, a Danish abstract reported a cost per life-year saved of DKK270k (US$48,000), a UK study reported a cost per QALY of GB£39,787 (US$78,000) and a Canadian study reported a cost per life-year saved of Can$91,332 (US$86,000). Regarding the long-term chronic support indication, the same Canadian study reported a cost per life-year saved of Can$59,842 (US$56,000), whereas a US study reported a cost per QALY of $36,255–60,057. Assuming a willingness to pay the threshold of GB£30,000 (US$59,000) per QALY, there is arguably stronger evidence to support the cost–effectiveness of LVAD technology for the long-term chronic support indication. However, the methodological quality of the majority of studies was poor, as was their generalizability, raising concerns over the reliability of these figures. With the limited and declining availability of donor hearts for transplantation, it appears that the future of this technology is in its use as long-term chronic support. Further analyses should be undertaken, particularly alongside randomized, controlled trials and utilizing second- and third-generation devices

PDF mon945.pdf - Other
Download (837kB)

More information

Published date: February 2008
Keywords: cost–effectiveness, end-stage heart failure, left ventricular-assist device, mechanical circulatory support, quality-adjusted life-year


Local EPrints ID: 72880
ISSN: 1477-9072
PURE UUID: 05f8747b-a724-4c85-bed7-1c0ddac25a17

Catalogue record

Date deposited: 24 Feb 2010
Last modified: 18 Jul 2017 23:52

Export record



Author: Julia Hutchinson
Author: David A. Scott
Author: Andrew J. Clegg
Author: Emma Loveman
Author: Pam Royle
Author: Jackie Bryant

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.